The massive epidemic of Ebola virus disease (EVD) in West Africa, followed in recent months by two outbreaks in the Democratic Republic of the Congo, underline the importance of this severe disease. Because Ebola virus (EBOV) must be manipulated under biosafety level 4 (BSL4) containment, the discovery and development of virus-specific therapies have been hampered. Recently, a transient transfection-based transcription-and replication competent virus-like particle (trVLP) system was described, enabling modeling of the entire EBOV life cycle under BSL2 conditions. Using this system, we optimized the condition for bulk co-transfection of multiple plasmids, developed a luciferase reporter-based assay in 384-well microtiter plates, and performed a highthroughput screening (HTS) campaign of an 8,354-compound collection consisting of U.S. Food & Drug Administration (FDA) -approved drugs, bioactives, kinase inhibitors, and natural products in duplicates. The HTS achieved a good signal-to-background ratio with a low percent coefficient of variation resulting in Z' = 0.7, and data points were reproducible with R 2 = 0.89, indicative of a robust assay. After applying stringent hit selection criteria of ≥70% EBOV trVLP inhibition and ≥70% cell viability, 381 hits were selected targeting early, entry, and replication steps and 49 hits targeting late, maturation, and secretion steps in the viral life cycle. Of the total 430 hits, 220 were confirmed by dose-response analysis in the primary HTS assay. They were subsequently triaged by time-of-addition assays, then clustered and ranked according to their chemical structures, biological functions, therapeutic index, and maximum inhibition. Several novel drugs have been identified to very efficiently inhibit EBOV. Interestingly, most showed pharmacological activity in treatments for central nervous system-related diseases. We developed and screened an HTS assay using the novel EBOV trVLP system. Newly identified inhibitors are useful tools to study the poorly understood EBOV life cycle. In addition, they also provide opportunities to either repurpose FDA-approved drugs or develop novel viral interventions to combat EVD.
Introduction
The 2014 Ebola virus (EBOV) outbreak was the most serious Ebola epidemic in recent history and was a major global threat to people and economies. The occurrence in recent months of two outbreaks in the Democratic Republic of the Congo underline the importance of this highly virulent virus. EBOV is a member of the Filoviridae family and is a filamentous, enveloped, negative-stranded RNA virus with a genome size of 18-19 kb encoding 7 proteins. EBOV disease (EVD) has been neglected for decades; neither EBOV-specific therapies nor vaccines are available because major patient populations live in low-income countries. In addition, EBOV is a causative agent of a severe form of viral hemorrhagic fever (VHF) with fatality rates as high as 90%. Therefore, research must be conducted in biosafety level 4 (BSL4) containments, which are limited worldwide. To overcome this, surrogate systems including virus-like particle (VLP) and minigenome systems that can be used in BSL2 facilities have been developed to study EBOV entry and replication, respectively (Hoenen et al., 2006; Edwards et al., 2015; Basu et al., 2015; Anantpadma et al., 2016) . These systems are limited to specific aspects of the virus life cycle. With the recent development of a transcription-and replication competent virus-like particle (trVLP) system for EBOV Watt et al., 2014) , it became possible to study almost all aspects of the viral life cycle by transferring cell culture supernatants from infected (transduced) target cells to naïve target cells (Fig. 1A) . One hallmark of this system is that besides entry and replication, it possible to evaluate EBOV morphogenesis and budding in only one single HTS campaign under BSL2 conditions. Furthermore, the EBOV trVLP system follows a more authentic and physiologically relevant approach compared to other surrogate systems because it does not depend on components from other unrelated viruses. In addition, proteins crucial for EBOV particle morphogenesis, budding, and entry are not overexpressed. Therefore, the EBOV trVLP system is an ideal platform to study unexploited steps in the EBOV life cycle and provides a powerful tool to discover novel viral interventions. Recently, the trVLP was shown to be a useful tool to characterize and to evaluate inhibitors in small-scale approaches (Nelson et al., 2016 (Nelson et al., , 2017 Dyall et al., 2018) .
Here, we report on the development and application of a target-free high-throughput screening (HTS) assay utilizing the novel EBOV trVLP system, which was miniaturized into 384-well microtiter plate format enabling rapid testing of large compound libraries. The EBOV trVLP system was validated using the previously reported EBOV inhibitors tamoxifen and toremifene (Johansen et al., 2013; Kouznetsova et al., 2014) . As a proof-of-concept, a small molecule collection containing U.S. Food & Drug Administration (FDA) -approved drugs, bioactives, kinase inhibitors, and investigational compounds was screened in duplicate to assess assay reproducibility and robustness. The identified compounds for entry and replication, morphogenesis, and budding were further confirmed by dose-response curve (DRC) analysis in the primary HTS assay, categorized according to their biological functions, and ranked according to their antiviral activities.
Material and methods

Cells and plasmids
The human embryonic kidney HEK293T cell line was grown at 37°C in 5% CO 2 . HEK293T cells were propagated in complete growth medium containing Dulbecco's minimum essential medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 Units/mL penicillin, and 100 g/mL streptomycin (P/S). All cell culture supplies were from Wellgene (Gyeongsan, Korea) and Invitrogen (Carlsbad, CA, USA). Plasmids for the EBOLA trVLP system (pCAGGS-NP, pCAGGS-VP35, pCAGGS-VP30, pCAGGS-L, p4cis-vRNA-RLuc, pCAGGS-T7, and pCAGGS-Tim1) were kindly provided by Dr. Thomas Hoenen (NIH/NIAID, Rocky Mountain Laboratories, Hamilton, MT, USA). Plasmids were amplified in DH5α competent cells (Intron Biotechnology, Seongnam, Korea) and extracted using EndoFree Plasmid Maxi Kit (Qiagen, Hilden, Germany) according to the manufacturer's specifications.
Production of EBOV trVLPs in p0 producer cells
HEK293T cells (10 7 in 20 mL) were seeded at into T175 flasks in complete growth media and incubated for 24 h. EBOV trVLP system plasmids were diluted from stocks in Opti-Mem (Gibco, Grand Island, NY, USA) with the following concentrations per T175 flask: pCAGGS-NP at 2.5 μg, pCAGGS-VP35 at 2.5 μg, pCAGGS-VP30 at 1.5 μg, pCAGGS-L at 20 μg, p4cis-vRNA-Rluc at 5 μg, and pCAGGS-T7 at 5 μg. The plasmids were combined to a total volume of 3.5 mL with 122 μL TransIT-LT1/T175 flask contents and incubated at room temperature for 15 min to promote complex formation. The transfection mixes were then gently added into T175 flasks. At 24 h post-transfection, the media was exchanged for 30 mL growth media with 5% FBS and 1% P/S and further incubated for an additional 48 h. All supernatants from p0 producer cells were collected followed by centrifugation at 2,000 rpm for 5 min and stored at −80°C until use. Cells were lysed after supernatant transfer to quantify virus production followed by addition of 1 mL Renilla-Glo (Promega, Madison, WI, USA). Relative luciferase unit (RLU) activity was measured using Victor III (PerkinElmer, Waltham, MA, USA).
Generation of EBOV trVLP p1 and p2 target cells
EBOV trVLP system plasmids were diluted from stock in Opti-MEM with the following concentrations per well of a 384-well microtiter plate: pCAGGS-NP at 1.6 ng, pCAGGS-VP35 at 1.6 ng, pCAGGS-VP30 at 0.9 ng, pCAGGS-L at 12.5 ng, and pCAGGS-Tim1 at 3.1 ng. The plasmids were combined to a total volume of 10 μL with 62 nL TransIT-LT1/well and incubated at room temperature for 30 min to promote complex formation. The transfection mixes were dispensed (Wellmate, Thermo Fisher Scientific, Waltham, MA, USA) into 384-well microtiter plates followed by HEK293T suspensions at 6000 cells/well in 20 μL complete growth media containing 8 μg/mL polybrene. After the reverse transfection procedure, the assay plates containing p1 and p2 target cells were incubated for 24 h until use.
Compound libraries
The library used for the screen combines 8354 small molecules obtained from commercial sources including: Spectrum Collection (MicroSource Discovery Systems, Gaylordsville, CT, USA), Prestwick Chemical Library (Prestwick Chemical, Illkirch, France), LOPAC ® 1,280
(Sigma-Aldrich, St. Louis, MO, USA), Tocriscreen compound Library (Tocris Bioscience, Bristol, UK), Anti-cancer & Kinase Inhibitor Library (Selleck Chemicals, Houston, TX, USA), and NIH Clinical Collection (Baltimore, MD, USA). The collection contains structurally diverse compounds from known drugs, experimental bioactives, kinase inhibitors, and pure natural products. These compounds target several therapeutic areas including oncology, infections, neuropsychiatry, cardiology, and immunology. All compounds were dissolved at a concentration of 10 mM in 100% dimethyl sulfoxide (DMSO, v/v) and formatted into 384-well polypropylene plates for storage at 20°C.
Screening of compound libraries with the EBOV trVLP system
To measure EBOV entry and replication, p1 target cells were seeded as previously described, and 1 μL compounds were transferred (Apricot Personal Pipettor, Apricot Design, Covina, CA, USA) from the compound library into an intermediate 384-well polypropylene plate. The compounds were mixed with 19 μL DMEM media, and 5 μL/well was transferred into 384-well assay plates and incubated with p1 cells for 2 h. Next, 15 μL EBOV trVLPs harvested from p0 producer cells were added and spin inoculated at 1000 rpm for 8 min. The plates were incubated for 72 h in a 37°C incubator. All compounds were screened at a final test concentration of 10 μM in 0.5% DMSO (v/v) . To determine EBOV secretion, p2 cells were seeded as described, and 20 μL cell culture supernatants were transferred from compound-treated p1 cells to p2 cells and spin inoculated at 1,000 rpm for 8 min. The assay plates were incubated for 72 h in a 37°C incubator. To measure luciferase reporter activity after 72 h, assay plates with p1 and p2 cells were transferred into the Cell Explorer automated robotic platform (PerkinElmer). Assay plates were equilibrated to room temperature, and 10 μL Renilla-Glo was added to each well with a bulk reagent dispenser (Multidrop, Thermo Fisher Scientific). After 10 min incubation, RLUs were measured using EnVision (PerkinElmer).
Determination of cell viability
To determine cell viability in the presence of compounds, HEK293T cells were seeded at 6000 cells/well in 45 μL complete growth media into 384-well assay plates and treated with 5 μL serially diluted compounds and incubated for 72 h. Cells were fixed with 10 μL paraformaldehyde at a final concentration of 2% (w/v) and stained with 5 μM Hoechst, followed by imaging using Opera (PerkinElmer).
Statistical evaluation of assays and compounds
To evaluate the quality of assay for HTS, the signal-to-background ratio (S/B) and the Z′-factor were determined using the following formulas (Zhang et al., 1999) : S/B = mean signal/mean background, Z′ factor = 1 − ([3σ c+ + 3σ c− ]/[|μ c+ − μ c− |]). S/B ratio is a simple measurement to assess signal window between positive control and background signal. Z′ factor is used in HTS/HCS to evaluate the performance of the assay and access the data variation. Z' factor values are 0 < Z < 0.5 that means signal window is small and 0.5 ≤ Z < 1 representing signal window is large and "high-quality" HTS assay. To find drug candidates from dose-response curve (DRC) analysis, Therapeutic index (TI) was determined using the formulas: TI = ratio of half maximal effective concentration (EC 50 )/half-maximal cytotoxicity concentration (CC 50 ).
Hit confirmation by dose-response curve analysis
For dose-response curve (DRC) analysis, hits were supplied from internal library stocks and transferred into intermediate 384-well polypropylene plates. Compounds were analyzed by 10-point serial doubling dilution, with final concentrations of 50, 25, 12, 6, 3, 1.5, 0.8, 0.4, 0. 2, and 0.1 μM (Apricot Personal Pipettor), and 5 μL volume of compounds were transferred into the assay plates. Reporter activity using luminescence readout and cell viability with imaging was performed as previously described.
Hit clustering and categorization
Confirmed hits were clustered based on scaffold analysis (Bemis and Murcko, 1996) , which defines the union of rings plus linker atoms connections using Vortex (Dotmatics, Bishop's Stortford, UK). To cluster the hits targeting early and late steps in the EBOV life cycle, we first generated a Bemis-Murcko scaffold of each compound using Vortex (Dotmatics) and grouped according to scaffold similarity. Next, the clustered molecules were reviewed to assess whether the structural groups were well defined within the respective scaffold. We combined information on the pharmacological actions of each compound from vendors and the ChemIDPlus database (National Library of Medicine, 2017), MESH database (National Library of Medicine, 2017), SciFinder (Chemical Abstract Services, 2017). All pharmacological actions including minor and major classifications were accounted for since known drugs and bioactives are reported to treat various diseases. Information on drug approval status was taken from the DrugBank database (Law et al., 2014) .
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Strategy and development of an EBOV trVLP HTS assay
Taking advantage of the recently described EBOV trVLP system, we implemented a strategy to develop an HTS assay in 384-well plate format . Briefly, the EBOV trVLP system is based on the transient transfection of 6 plasmids expressing viral proteins and a minigenome that is initially artificially T7 RNA polymerase driven. Sufficient amounts of EBOV trVLPs are produced upon transfection of HEK293T cells (producer cells, p0). Cell culture supernatants are harvested and transferred to target HEK293T cells (p1) that are transiently transfected with factors crucial for viral entry, replication, and particle morphogenesis (Fig. 1A) . By transferring cell culture supernatants from infected (transduced) p1 cells to p2 cells, the entire EBOV life cycle can be targeted under authentic conditions. This transcomplementation strategy is key to safely handling EBOV in BSL2 containment.
To identify the most efficient and convenient way of transient transfection of multiple plasmids, we first tested several conditions for bulk co-transfection of the 6 plasmids towards large-scale EBOV trVLP production in p0 cells. Two different transfection reagents were tested side-by-side with 1:3 ratios of plasmid to reagent mix based on the published approach in 6-well plates ( Fig. 1B) (Watt et al., 2014) . The resulting transfection efficiency of EBOV trVLP from p0 producer cells was assessed by measuring luciferase activity. Comparing the two reagents, transfection with TransIT-LT1 resulted in up to 10-fold greater reporter activity compared to Lipofectamine 2000. Therefore, TransIT-LT1 was selected for further transfection experiments with a plasmid to reagent ratio of 1:3 to enable maximum complex formation for 6 plasmids. To produce sufficient EBOV trVLPs for HTS, we systematically tested bulk forward and reverse transfection in T75 and T175 flasks. Reverse transfection was performed by incubating plasmid mixtures and cell suspensions before seeding; whereas cells were seeded 24 h prior to transfection in forward transfection. A luminescence comparison between the two processes showed that forward transfection yielded a > 20-fold higher transfection efficiency than reverse transfection independent of flask size (Fig. 1C) . Therefore, EBOV trVLPs production in T175 flasks was selected due to a larger EBOV trVLP yield in the supernatant volume.
Next, to establish infection conditions in 384-well plate format, we evaluated the efficiency of EBOV trVLPs under varying cell seeding densities of 3,000, 6,000, 9,000, and 12,000 cells/well (Fig. 1D ). Z′ factors were calculated by comparing luciferase activities of infected cells treated with 0.5% DMSO (v/v) and non-infected cells. The results showed that 6000 cells/well achieved the best overall performance as measured by the Z' factor of 0.7 and the highest overall infection efficiency based on RLU readout.
Using these infection and cell-seeding conditions, we next focused on the optimization of p1 cells in 384-well plates by testing different transfection conditions. Several methods shown in Table 1 were tested, including pre-mixture of cells with transfection reagents plus plasmids, reverse transfection with plasmid complex followed by cell seeding, and forward transfection with cell seeding followed by plasmid complex addition at various time points (Fig. 1E) . As a direct comparison, the same batch of p0 EBOV trVLPs was used in this experiment. Method B using reverse transfection with complex formation yielded the highest infection rate with an average of 1.5 × 10 6 RLUs.
In summary, we evaluated the sequential steps of the assay: 1) transfection conditions for bulk production of trVLPs in p0 cells in flasks, 2) infectivity of p0 produced trVLPs in p1 cells under different seeding conditions in 384-well microtiter plates, and 3) infectivity of p0 produced trVLPs in p1 cells under different cell transfection conditions to establish the EBOV trVLP p1 system in 384-well microtiter plates. As a proof-of-concept, we evaluated the inhibitory activities of tamoxifen, trifluoperazine, clomipramine, and toremifene, which were previously described to inhibit EBOV trVLP infection ( Fig. 1F) (Johansen et al., 2013; Kouznetsova et al., 2014) . Inhibitory activity was assessed in p1 cells using luminescence readout, and the half maximal effective concentration (EC 50 ) values of compounds were calculated. Based on the antiviral activity observed by EC 50 and maximum inhibition in percent (Imax (%)) (Table 2) , we selected tamoxifen and toremifene as reference drugs for our EBOV trVLP HTS. For HTS assay quality and analysis, toremifene at 10 μM was used as a positive control, because of reproducible 100% inhibition without cytotoxicity through the independent experiments. We optimized co-transfection and cell plating conditions to generate p0 producer and p1 cells, selected reference compounds, and produced sufficient amounts of EBOV trVLP for the HTS campaign.
EBOV trVLP HTS assay automation
As the next step toward HTS with the EBOV trVLP system, the assay was adapted for automated liquid handling of cell seeding, reagent dispensing, compound treatment, and supernatant transfer from p1 into p2 target cells. First, we compared manual and automated dispensing of 25 μL luciferase reagent. RLUs were in the range of 3.8 × 10 6 using a manual pipettor; however, automated dispensing resulted in a ∼88-fold reduction due to bubbling from the lysis buffer containing detergent, which interfered with the overall RLU signal ( Fig. 2A) . Consequently, the automated dispensing volume was adjusted to 10 μL to minimize the overall agitation, and this resulted in RLUs similar to the tamoxifen, trifluoperazine, clomipramine, and toremifene. Compound concentration, EBOV trVLP inhibition in percent, and cell viability in percent are depicted on the x-, left y-(black), and right y-axis (red), respectively. manual process at a reduced reagent cost per well.
To assess the impact of compounds on the entire EBOV life cycle, we employed a supernatant transfer strategy in which cell culture supernatants were transferred from p1 to naïve p2 cells. The supernatant transfer process was evaluated using the following criteria of acceptance: uniform supernatant transfer, minimal cell monolayer disturbance during the transfer process, low well-to-well variation across an entire 384-well microtiter plate, and high infectivity between EBOV trVLPs released in p1 into p2 cells. Various supernatant volumes were tested using the liquid transfer station, and we selected a 20 μL supernatant transfer that resulted in overall uniformity between wells and no disturbance of the cell monolayer. To measure RLUs, p1 cells were treated with 0.5% DMSO (v/v) and toremifene at 10 μM in 0.5% DMSO (v/v) for 2 h followed by supernatant transfer to p2 cells (Fig. 2B) . The signal-to-background ratio (S/B) between DMSO-and toremifenetreated cells was approximately 100-fold in p1 cells; however, after supernatant transfer, the window was reduced to 7-fold in p2 cells. To Z′ factor calculated using 0.5% DMSO (v/v) and 10 μM toremifene. S/B: signalto-background ratio: %CV, coefficient of variation. increase the window of measurement, EBOV trVLPs were spin inoculated, which resulted in nearly 300-and 100-fold windows in p1 and p2 cells, respectively. Z′, S/B, and %CV values were calculated and are shown in Table 3 . Spin inoculation was therefore incorporated in the HTS assay to achieve Z' > 0.5, increase the S/B ratio, and reduce the %CV. The EBOV trVLP HTS assay work flow is shown in Fig. 2C .
EBOV trVLP HTS assay validation, drug screening, and hit selection
Using the optimized and fully automated EBOV trVLP HTS assay conditions, we validated the assay by running controls in 384-well microtiter plates. Entire plates were treated with 0.5% DMSO (v/v) and toremifene at 10 μM in 0.5% DMSO (v/v) to monitor reproducibility and well-to-well variations. A heat map analysis of p1 cells demonstrated signal uniformity across the plate of DMSO and toremifene controls, with good separation of the controls (Fig. 3A) . Luminescence was measured at ∼3 × 10 6 RLUs and ∼1 × 10 3 RLUs in cells treated with DMSO and toremifene, respectively, resulting in an S/B ratio of 3000 and Z′ of 0.63. After supernatant transfer to p2 cells, similar uniformity of signal was observed (Fig. 3B) , whereas the total RLUs of DMSO were reduced by 2-fold to ∼1.5 × 10 6 RLUs and in toremifenetreated cells to ∼2 × 10 4 RLUs. The resulting S/B ratio of the controls in p2 with the EBOV trVLP system was acceptable at 20-fold. No systematic errors were observed, and the S/B ratio of 100 and Z' of 0.55 demonstrated that assay quality and performance were suitable for HTS. After the successful HTS assay validation, we screened compound libraries consisting of a collection of 8354 small molecules containing bioactives with known targets (66%), FDA-approved drugs (28%), natural compounds (3%), and kinase inhibitors (3%). Compounds were screened in duplicates at a final concentration of 10 μM in 0.5% DMSO (v/v). For each replicate, two reference DRC plates containing EBOV inhibitor toremifene was included at a starting concentration of 100 μM in 0.5% DMSO (v/v) with 2-fold serial dilutions. EC 50 and half-maximal cytotoxicity concentration (CC 50 ) value of reference compound was compared to previously reported data as a measure of assay robustness throughout the screen (Table 4 ). The EC 50 values of toremifene in p1 and p2 cells were 0.14 μM and 0.18 μM, respectively, with an CC 50 > 20 μM (Fig. 3C) . Toremifene shows activity in p2 cells, because after inhibiting viral entry in p1 cells, fewer cells are infected which can replicate and secrete progeny virus. Consequently, after supernatant transfer from p1 to p2 cells this is reflected by a lower number of infectious particle leading to a reduced infection rate. These results demonstrated the assay's ability to identify inhibitors in the entire EBOV life cycle.
After screening 8,354 compounds, results of infected p1 cells were evaluated using a scatter plot analysis to monitor data point distribution (Fig. 3D, left) . Replicate results in sets 1 and 2 were plotted to measure Z' and R 2 values of 0.66 and 0.89, respectively, reflecting high assay robustness and reproducibility. Controls performed as expected for 0.5% DMSO (v/v) and 10 μM toremifene at 0% and 100% inhibition, respectively. To select for entry and replication inhibitors, we utilized threshold selection criteria of ≥70% inhibition of EBOV trVLP reporter activity and ≥70% cell viability to nominate 381 compounds (Fig. 3D , middle). To select for morphogenesis and secretion inhibitors using the supernatant transfer strategy from p1 to p2 cells, we performed a linear regression analysis (Fig. 3D, right) . A majority of compounds showed a correlation in activity between p1 and p2 cell % inhibition (fill line).
Compounds below 20% inhibition in p1 were excluded due to background and those above 90% inhibition were excluded as potent (dash line). Next, compounds were selected with activity as morphogenesis and secretion inhibitors by the difference between p1 and p2 measurements. Finally, cytotoxic compounds were removed from the list and 49 compounds are selected as late-stage inhibitors. In total, 430 compounds were identified to inhibit EBOV trVLPs in p1 and p2 assays.
Hit confirmation
To confirm the antiviral activities of the 430 selected hits, compounds were supplied from internal library stocks and evaluated in the primary HTS assay by DRC analysis of serially diluted compounds. Besides calculating EC 50 and CC 50 values, and the resulting therapeutic index (TI), we also determined the Imax (%) as an additional criterion to prioritize hits. Of the selected compounds tested, 220 were confirmed in DRC analysis by applying a stringent hit confirmation criteria of TI ≥ 6 in p1 cells. These included 65 previously identified EBOV inhibitors and 1 confirmed in p2 cells. As a representative of the compounds confirmed by DRC analysis, 4 previously published EBOV inhibitors (Fig. 4A ) and unpublished inhibitors (Fig. 4B) are shown. Additionally, the EC 50 and CC 50 values with their activities and pharmacologic actions are summarized in Table 5 . Among the compounds selected for inhibiting EBOV in p2 cells (late steps including secretion), Bisacodyl showed no inhibitory activity in p1 cells (Fig. 4C ), while p2 cell infection was dose-dependently inhibited with an EC 50 of 1.89 μM and Imax of 73% (Table 6 ). This phenotype is characteristic for inhibitors interfering with late steps of the EBOV life cycle, like virion morphogenesis or egress. Furthermore, we confirmed the previously described EBOV entry inhibitors ML9, amodiaquine, sertraline, toremifene, bepridil and amiodarone and additionally identified five new drugs (iminodyn 17, nobiletin, ferroquine, N-Acetyl-L-leucyl-L-leucyl-Lmethional, calpeptin) as shown in Table 7 .
Hit triage and classification according to pharmacological actions
Among our confirmed hits, we selected two unpublished cathepsin L (CatL) inhibitors. N-Acetyl-L-leucyl-L-leucyl-L-methional, a highly potent inhibitor of CatL with lower inhibitory activity against cathepsin B (CatB), and calpeptin, which has been demonstrated to inhibit the CatL and cathepsin K were subjected to time-of-addition experiments to assess the antiviral activities during EBOV entry. Compounds were added to cells 16 h before or post-virus inoculation. Both CatL inhibitors showed exclusively anti-EBOV activity under the pretreatment condition (Fig. 5A ), but only minor inhibition of infection was detected when the compounds were added 16 h post-virus inoculation (Fig. 5B) . These results confirmed the antiviral activity of our newly identified CatL inhibitors during the early step of EBOV entry. EC 50 and CC 50 values from time-of-addition experiments are shown in Table 8 . In contrast, cyanocobalamin, one of our newly identified inhibitors, showed similar antiviral activity under both time-of-addition assay conditions, indicating it functions after EBOV entry. Finally, the 220 confirmed hits were classified according to scaffold similarities and reported biological activities for further analysis. The pharmacological actions spanned 24 categories, with the most confirmed drugs in the area of Values represent mean ± SD from 3 independent experiments.
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Discussion
Since EVD was discovered in 1976, EBOV outbreaks are reported on a nearly annual basis. The EBOV outbreak in 2014 with more than 11,000 casualties in West Africa (Baize et al., 2014) , prompted governments to support research campaigns addressing unmet medical needs. This effort led to the development of the EBOV trVLP system, which allows for interrogation of the entire EBOV life cycle through entry, replication, and trVLP release under safe BSL2 conditions (Hoenen et al., 2006) . The importance of this work has now been underscored by the occurrence in recent months of two outbreaks in the Democratic Republic of the Congo (http://www.who.int/ebola/en/).
In this report, we describe the utility of this system, the development of an HTS assay, and the results of screening 8354 compounds consisting of FDA-approved drugs and bioactives with known activities that can be quickly repurposed for therapeutic use and/or to study the mechanism of action to better understand the EBOV life cycle. The EBOV trVLP system is based on the transient transfection of six plasmids, which requires identifying suitable assay conditions to monitor viral entry, replication, and secretion. We evaluated various factors including cell numbers, transfection and inoculation procedures, and reference inhibitors to develop a robust 384-well plate assay. Toremifene and tamoxifen were selected as reference inhibitors and performed as previously reported using live virus, demonstrating that the trVLP system is a suitable tool to screen for drugs or targets . After defining the HTS protocol, we validated the assay by infecting entire 384-well plates with EBOV trVLPs in the presence and absence of toremifene (EC 100 ) and demonstrated uniformity of infection by heat map analysis and calculated the S/B ratio of 850 and 74 in p1 and p2 cells, respectively. Compounds were subsequently screened at 10 μM in 0.5% DMSO (v/v) in duplicates. The HTS campaign was shown to be highly robust and reproducible as demonstrated by Z' and R 2 values of 0.66 and 0.89, respectively. Active compounds were selected by applying strict hit selection criteria of ≥70% EBOV replication inhibition and ≥70% cell viability to rule out those in which antiviral activity is influenced by cytotoxicity. This identified 381 and 49 hits in p1 and p2 cells, respectively. The nominated hits were supplied from internal library stocks, and 220 were confirmed in p1 and p2 cells by 10-point DRC analysis in the primary HTS assay. Among the confirmed hits, 174 compounds were classified as high priority with TI values of 6-331, and 65 compounds were previously published or patented as EBOV inhibitors using various cell culture systems. As shown in Table 5 , inhibitors tamoxifen, AY-9944, paroxetine maleate, and thioridazine were previously identified by using an EBOV VLP entry assays, with EC 50 values in a comparable range to our results. This is suggesting that surrogate systems for EBOV entry using VLPs bearing the viral glycoproteins and the EBOV trVLP system exploit an identical entry mechanism and kinetics. Furthermore, CatB and CatL, both endosomal cysteine proteases, have been shown to be required for EBOV entry (Chandran et al., 2005) . Both proteases are involved in the cleavage of EBOV GP1, which is an essential step in triggering fusion between the viral envelope and endosomal membrane and resulting in the release of the viral genome into the cytoplasm for replication. CatB and CatL are promising targets for anti-EBOV drugs and several inhibitors have been described.
In addition, we re-identified previously reported inhibitors like ML9, amodiaquine, sertraline, bepridil and amiodarone which are targeting described EBOV entry factors like myosin light chain kinase, CatB-dependent viral GP cleavage, and NPC1-dependent viral fusion. The remaining 109 high priority hits have not been reported yet and include inhibitors targeting different components of already described cellular restriction factors for EBOV entry such as the dynamin I and II GTPase inhibitor iminodyn 17, the endosomal acidification inhibitor ferroquine and CatL inhibitors N-Acetyl-L-leucyl-L-leucyl-L-methional and calpeptin. Similarly, the phosphoinositide-3 kinase-Akt pathway inhibitors demethylasterriquinone B1 and nobiletin were identified among the high-priority anti-EBOV hits. The identification of these potent inhibitors illustrate the sensitivity of our EBOV trVLP assay and confirm their corresponding specific cellular targets to be restrictive for EBOV entry using HIV-based VLPs pseudotyped with EBOV glycoproteins (Mulherkar et al., 2011; Saeed et al., 2008; Sun et al., 2017; WoolLewis and Bates, 1998; Zhou et al., 2016; Schornberg et al., 2006) . Additionally, for phosphoinositide-3 kinase inhibition, we have newly identified 4 more anti-EBOV compounds interfering on different levels of the epidermal growth factor receptor (EGFR) signaling pathways. Furthermore, G-protein coupled receptors (GPCR) modulators identified in the screen include antagonists and agonists of histamine, dopamine, adrenergic and 5-HT (serotonin) receptors that were already published as cellular targets for EBOV entry (Cheng et al., 2015) . We also identified several compounds targeting GPCRs like cannabinoid, κ- The mean ± SD of duplicate experiments are shown. Not determined (N.D.).
N. Lee et al. Antiviral Research 158 (2018) 226-237 opioid, δ-opioid, nociceptin opioid peptide (NOP), and neurokinin 1 receptors. Together with other kinase inhibitors, these compounds are represented in the pharmacological group of protein and cellular kinase inhibitors (Fig. 5C ) that were described having a broad-spectrum antiviral activity for hemorrhagic fever viruses like EBOV (Mohr et al., 2015) . In addition to the reported EBOV entry inhibitors, we re-identified several previously published EBOV RNA synthesis inhibitors in p1 cells, such as azacitidine, gedunin, mycophenolic acid, and cycloheximide (Edwards et al., 2015) . Time-of-addition assays revealed that our cathepsin L inhibitors act exclusively in viral entry during the first 16 h post-infection, whereas the newly identified cyanocobalamin also showed strong inhibition after the establishment of infection and therefore is most likely active in an EBOV life cycle step like replication ( Fig. 5A and B) . Important to note, bisacodyl is to our knowledge the first reported inhibitor to specifically interfere with EBOV morphogenesis and egress which does not belong to the class of quinoxalinebased inhibitors (Loughran et al., 2016) . Collectively, our data demonstrate that the EBOV trVLP system is suitable for identifying novel inhibitors targeting viral entry, replication, as well as morphogenesis and egress. The re-identification of previously described EBOV entry and replication inhibitors suggests that the trVLP entry mechanism is comparable to other used surrogates and the authentic EBOV system and confirms the authenticity of EBOV trVLP entry in p1 cell infection.
In conclusion, we screened FDA-approved drugs and biological actives using the EBOV trVLP system and identified 220 compounds that efficiently inhibit various stages of the viral life cycle. Several of these drugs have already been used for EBOV treatments, such as amodiaquine, which is a cationic amphiphilic drug (CAD) similar in structure to chloroquine, a previously described EBOV entry inhibitor. During the 2014 EBOV outbreak, the treatment of selected malaria patients in Liberia were switched from antimalarial containing lumefantrine to one containing amodiaquine and noted a significant decrease in case fatality rates in Ebola treatment centers. Furthermore, the anti-arrhythmic drug amiodarone, also a CAD, was tested in clinical trials in 65 patients at up to 20 mg/kg/day during the 2014 EBOV outbreak in Freetown, Sierra Leone. The reported case fatality rate was 40% compared with 50% for the entire patient population (http://www.who.int/medicines/ebolatreatment/2015_0703TablesofEbolaDrugs.pdf). As mentioned by the WHO, it cannot be excluded that decreasing fatalities were due to lesser toxicity of amodiaquine compared to artemether-lumefantrine and it is not known whether the effect described in patients treated with amiodarone is significant. However, while further investigations on a potential anti-EBOV activity of amodiaquine and amiodarone in animals are needed, our and others in vitro results are indicating that an antiviral activity of the compounds may have been responsible for the effects observed in EBOV patients. Drug repurposing strategies can be suitable to identify effective, affordable, and accessible EVD therapies and in vitro screening campaigns are powerful tools to identify drug candidates. Currently, we are evaluating several confirmed hits in a collaborative study using authentic EBOV in BSL4 containment to quickly repurpose favorable FDA-approved drugs as urgently needed EVD treatments.
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